Inhibikase Therapeutics, Inc.
IKTNasdaq
$2.11
↑ +5.0%Jul 17 close · end-of-day
Price
1Y↑ +13.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$363.6M
Enterprise Value
$242.8M
P/E
—
P/S
—
P/B
2.2
EV/EBITDA
—
PEG
—
FCF Yield
-9.8%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$51.0M
Free Cash Flow (TTM)
-$35.7M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-30.4%
ROIC
-93.2%
Debt / Equity
—
Net Cash
$120.8M
Return 1Y
+11.1%
Company profile
Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD.
- CEO
- Milton H. Werner
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 6
- Headquarters
- Georgia
- Website
- inhibikase.com
Management & directors
- Cabell ChristopherPresident & Head of R&D
Roles derived from SEC Form 4 filings.
Earnings
IKT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00—
Diluted EPS-$0.10↓ -33.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $698,468.00 | $3.1M | $123,440.00 | $260,501.00 | $0.00 | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$2.8M | -$14.8M | -$18.1M | -$20.1M | -$28.6M | -$52.0M |
| Net income | -$2.8M | -$14.8M | -$18.1M | -$19.0M | -$27.5M | -$48.3M |
| Diluted EPS | — | -$0.81 | -$4.28 | -$3.16 | -$1.16 | -$0.49 |
| Operating cash flow | -$1.1M | -$14.3M | -$17.4M | -$18.1M | -$19.1M | -$27.8M |
| Free cash flow | — | -$14.3M | -$17.6M | -$18.1M | -$19.1M | -$27.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -403.5% | -476.2% | -14686.2% | -7712.0% | — | — |
| Net margin | -407.7% | -476.9% | -14625.9% | -7304.7% | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$5.1M | -$5.8M | -$12.9M | -$14.6M | -$10.8M | -$12.8M | -$13.8M | -$17.8M |
| Net income | -$5.0M | -$5.8M | -$12.1M | -$13.7M | -$9.9M | -$11.9M | -$12.7M | -$16.4M |
| Diluted EPS | -$0.66 | -$0.65 | $0.88 | -$0.15 | -$0.11 | -$0.13 | -$0.10 | -$0.10 |
| Operating cash flow | -$5.1M | -$4.9M | -$5.3M | -$4.1M | -$5.6M | -$10.6M | -$7.5M | -$12.1M |
| Free cash flow | -$5.1M | -$4.9M | -$5.3M | -$4.1M | -$5.6M | -$10.6M | -$7.5M | -$12.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-02-21 | Aurentz Vincent | D | 255,299 | $0.00 | $0.00 | filing |
| 2026-02-21 | Cabell Christopher· President & Head of R&D | D | 338,282 | $0.00 | $0.00 | filing |
| 2026-02-21 | Munshi Amit | D | 19,089 | $0.00 | $0.00 | filing |
| 2025-11-21 | Sands Capital Life Sciences Pulse Fund II, L.P. | Buy | 2,068,965 | $1.45 | $3.0M | filing |
Latest 4 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.